Published in Chest on September 01, 2008
Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol (2009) 2.05
Genome-wide association identifies regulatory Loci associated with distinct local histogram emphysema patterns. Am J Respir Crit Care Med (2014) 1.57
Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res (2011) 1.52
The Asthma-COPD Overlap Syndrome: A Common Clinical Problem in the Elderly. J Allergy (Cairo) (2011) 1.49
Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. Thorax (2014) 1.48
Quantitative computed tomography in COPD: possibilities and limitations. Lung (2011) 1.35
Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest (2013) 1.32
Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation. Respir Res (2010) 1.10
The relationship between lung function impairment and quantitative computed tomography in chronic obstructive pulmonary disease. Eur Radiol (2011) 1.09
Early chronic obstructive pulmonary disease: definition, assessment, and prevention. Lancet (2015) 0.92
Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial. Respir Res (2011) 0.87
Therapeutic Approaches to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis. Ann Am Thorac Soc (2016) 0.87
Integrative genomics of chronic obstructive pulmonary disease. Biochem Biophys Res Commun (2014) 0.82
Exome Array Analysis Identifies a Common Variant in IL27 Associated with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2016) 0.81
Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases. F1000Prime Rep (2015) 0.81
Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities. Pharmacogenomics (2010) 0.80
Functional characterization of the matrix metalloproteinase-1 cigarette smoke-responsive region and association with the lung health study. Respir Res (2012) 0.77
Recognizing the Many Faces of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2016) 0.75
Health and social impacts of COPD and the problem of under-diagnosis. Multidiscip Respir Med (2014) 0.75
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 10.97
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17
Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med (2015) 4.16
Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70
C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 3.69
Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44
What is chronic obstructive pulmonary disease anyway?: Continua, categories, cut points, and moving beyond spirometry. Am J Respir Crit Care Med (2013) 3.39
Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med (2012) 3.00
FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J (2013) 2.87
Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med (2010) 2.80
Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA (2013) 2.59
'Highlights from this issue’ in the November issue of Thorax. Thorax (2013) 2.59
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One (2012) 2.52
Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.21
Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest (2009) 2.20
Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol (2002) 2.16
Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.99
A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98
Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 1.79
A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest (2007) 1.79
Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.72
Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax (2012) 1.72
Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest (2006) 1.72
Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc (2015) 1.72
Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J (2013) 1.66
Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently. Am J Respir Crit Care Med (2010) 1.66
Predictors of objective cough frequency in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.64
[Prevalence of chronic obstructive pulmonary disease in Copenhagen. Results from The Copenhagen City Heart Study]. Ugeskr Laeger (2007) 1.62
Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med (2005) 1.60
COPD: the dangerous underestimate of 15%. Lancet (2006) 1.60
Chronic bronchitis in an elderly population. Age Ageing (2003) 1.51
[Chronic obstructive pulmonary disease. Admission, course and prognosis]. Ugeskr Laeger (2003) 1.49
Overweight and obesity may lead to under-diagnosis of airflow limitation: findings from the Copenhagen City Heart Study. COPD (2014) 1.43
Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients. Respir Med (2010) 1.41
Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med (2013) 1.41
Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: A longitudinal study of the general population. Ann Intern Med (2002) 1.41
Possible gene dosage effect of glutathione-S-transferases on atopic asthma: using real-time PCR for quantification of GSTM1 and GSTT1 gene copy numbers. Hum Mutat (2004) 1.37
Changes in alcohol intake and mortality: a longitudinal population-based study. Epidemiology (2004) 1.32
Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med (2010) 1.30
Long-term survival for COPD patients receiving noninvasive ventilation for acute respiratory failure. Int J Chron Obstruct Pulmon Dis (2013) 1.30
Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir Care (2011) 1.29
Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc (2011) 1.28
MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 1.27
Cardiovascular events in patients with COPD: TORCH study results. Thorax (2010) 1.25
Impulse oscillometry in COPD: identification of measurements related to airway obstruction, airway conductance and lung volumes. Respir Med (2008) 1.19
Natural histories of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2008) 1.11
Smoking cessation intervention in a large randomised population-based study. The Inter99 study. Prev Med (2005) 1.10
It is possible to help smokers in early motivational stages to quit. The Inter99 study. Prev Med (2005) 1.10
Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respir Res (2011) 1.08
C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax (2010) 1.07
Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. Respir Med (2009) 1.06
Short telomere length, lung function and chronic obstructive pulmonary disease in 46,396 individuals. Thorax (2012) 1.04
Validation of a chronic obstructive pulmonary disease screening questionnaire for population surveys. Respir Med (2004) 1.04
α₁-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest (2010) 1.02
Biomarkers in chronic obstructive pulmonary disease. Proc Am Thorac Soc (2009) 1.01
Improved survival prediction from lung function data in a large population sample. Respir Med (2008) 1.00
Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population. J Gen Intern Med (2014) 1.00
The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. Int J Chron Obstruct Pulmon Dis (2009) 0.98
Aortic augmentation index: reference values in a large unselected population by means of the SphygmoCor device. Am J Hypertens (2009) 0.98
Characteristics of undertreatment in COPD in the general population. Chest (2013) 0.97
COPD stage and risk of hospitalization for infectious disease. Chest (2008) 0.97
COPD phenotype description using principal components analysis. Respir Res (2009) 0.97
[An overview of Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD) (revised 2011)]. Zhonghua Yi Xue Za Zhi (2012) 0.96
Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med (2003) 0.96
Prevalence of COPD in Copenhagen. Respir Med (2010) 0.95
A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob Res (2004) 0.95
Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. Respir Res (2011) 0.95
Genetic influences on Chronic Obstructive Pulmonary Disease - a twin study. Respir Med (2010) 0.93
Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report. COPD (2011) 0.93
Association between vitamin D status and COPD phenotypes. Lung (2014) 0.92
Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes? Ann Nutr Metab (2013) 0.91
High aortic augmentation index predicts mortality and cardiovascular events in men from a general population, but not in women. Eur J Prev Cardiol (2012) 0.91
Smoking reduction and biomarkers in two longitudinal studies. Addiction (2006) 0.90
Multistudy fine mapping of chromosome 2q identifies XRCC5 as a chronic obstructive pulmonary disease susceptibility gene. Am J Respir Crit Care Med (2010) 0.89
Substantial need for early diagnosis, rehabilitation and treatment of chronic obstructive pulmonary disease. Dan Med J (2012) 0.89
Family based association analysis of the IL2 and IL15 genes in allergic disorders. Eur J Hum Genet (2006) 0.89
Acceptance of the smoking cessation intervention in a large population-based study: the Inter99 study. Scand J Public Health (2005) 0.88
Resting heart rate is a predictor of mortality in COPD. Eur Respir J (2012) 0.87
Cigarette smoke in research. Am J Respir Cell Mol Biol (2004) 0.87
Socioeconomic status and prognosis of COPD in Denmark. COPD (2014) 0.86
Can patients with COPD self-manage? Lancet (2012) 0.86
A functional CD86 polymorphism associated with asthma and related allergic disorders. J Med Genet (2007) 0.86
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc (2015) 0.85
Chronic cough and phlegm in young adults: should we worry? Am J Respir Crit Care Med (2007) 0.85
Validation of the i-BODE index as a predictor of hospitalization and mortality in patients with COPD participating in pulmonary rehabilitation. COPD (2013) 0.85
Vitamin D, vitamin D binding protein, lung function and structure in COPD. Respir Med (2013) 0.84
COPD assessment: I, II, III, IV and/or A, B, C, D. Eur Respir J (2014) 0.84
Management and survival of patients admitted with an exacerbation of COPD: comparison of two Danish patient cohorts. Clin Respir J (2010) 0.84
Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. Respir Res (2014) 0.83
Cardiovascular morbidity in COPD: A study of the general population. COPD (2010) 0.83
Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation. Curr Drug Targets (2013) 0.83
Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD. Respir Med (2013) 0.82
Smoking reduction intervention in a large population-based study. The Inter99 study. Prev Med (2005) 0.82
Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. BMC Pulm Med (2014) 0.81
COPD: a prevalence estimation model. Respirology (2005) 0.81